Record $688M Merck Settlement May Not Be Contagious

Law360, New York (February 14, 2013, 8:17 PM EST) -- Despite the eye-popping size of Merck & Co.’s record $688 million stock-drop settlement Thursday, experts say the deal might not prove to be a tipping point in securities fraud cases that target deep-pocketed pharmaceutical firms.

The deal resolves two class actions alleging Merck and subsidiary Schering-Plough hid test results for their anti-cholesterol drug Vytorin from investors. If approved by a New Jersey federal judge, it would become the largest securities fraud settlement in history by a pharmaceutical company, and one of the top-25 largest deals across all industries. Previously, the largest stock settlement by a drug company was a $300 million...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS